Evidence map›Paper›PMID 35199969›Full record

ArticleCPT: pharmacometrics & systems pharmacology2022

Efficient simulation of clinical target response surfaces.

Daniel Lill, Anne Kümmel, Venelin Mitov, Daniel Kaschek, Nathalie Gobeau, Henning Schmidt, Jens Timmer

Open access · goldAbstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Efficient simulation of clinical target response surfaces.CPT: pharmacometrics & systems pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Daniel LillIntiQuan GmbH, Basel, Switzerland.ORCID 0000-0002-1058-4826
Anne KümmelIntiQuan GmbH, Basel, Switzerland.
Venelin MitovIntiQuan GmbH, Basel, Switzerland.ORCID 0000-0002-5227-5191
Daniel KaschekIntiQuan GmbH, Basel, Switzerland.
Nathalie GobeauMedicines for Malaria Venture, Geneva, Switzerland.
Henning SchmidtIntiQuan GmbH, Basel, Switzerland.
Jens TimmerInstitute of Physics, University of Freiburg, Freiburg, Germany.
University of Freiburg · DEMedicines for Malaria Venture · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Simulation of combination therapies is challenging due to computational complexity. Either a simple model is used to simulate the response for many combinations of concentration to generate a response surface but parameter variability and uncertainty are neglected and the concentrations are constant-the link to the doses to be administered is difficult to make-or a population pharmacokinetic/pharmacodynamic model is used to predict the response to combination therapy in a clinical trial taking into account the time-varying concentration profile, interindividual variability (IIV), and parameter uncertainty but simulations are limited to only a few selected doses. We devised new algorithms to efficiently search for the combination doses that achieve a predefined efficacy target while taking into account the IIV and parameter uncertainty. The result of this method is a response surface of confidence levels, indicating for all dose combinations the likelihood of reaching the specified efficacy target. We highlight the importance to simulate across a population rather than focus on an individual. Finally, we provide examples of potential applications, such as informing experimental design.

Indexed as

AlgorithmsResearch DesignComputer SimulationHumansModels, BiologicalProbabilityUncertainty

Identifiers

PMID35199969
PMCPMC9007598
OpenAlexW4213422890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.